Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Background: A-319 is a CD19 x CD3 bispecific T cell engager to treat B-cell non-Hodgkin Lymphoma (B-NHL). A-319 contains a scFV domain derived from SP34 CD3 antibody and a CD19 binding domain in a Fab format without Fc. A-319 has the same mechanism of action as that of blinatumomab, and may benefit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.6158-6158
Hauptverfasser:	Liu, Wei Ping, Jiang, Bo, Shuang, Yue Rong, Zhao, Xing, Zhong, Xuan Fan, Tan, Ying, Yu, Guo Jian, Xue, Sheng Jie, Shen, Wu Zhong, Tu, Gui Yun, Yang, Zheng, Chen, Han Yang, Xu, Jason, Liu, Shui, Yan, Xiao Qiang Qiang, Zhu, Jun, Song, Yu Qin
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!